Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 11;44(1):252–262. doi: 10.3892/or.2020.7610

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Ohkuma et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Identification of chemotherapy resistance-related molecules. (A and B) NGS analysis for the (A) GEM administration and (B) GEM + nab-PTX administration groups. Treatment resistance score was defined as the NE value ratio (treated group/control group) × NE value difference (treated group-control group). (C and D) The ratio of NE values for pIgR expression between the treated and control groups tended to be greater than 1.0 for most of the PDXs treated with (C) GEM or (D) GEM + nab-paclitaxel. NGS, next-generation sequencing; GEM, gemcitabine; nab-PTX, nab-paclitaxel; NE, normalized expression; pIgR, polymeric immunoglobulin receptor; PDX, patient-derived xenografts.